A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Oral Doses Of Pf-04937319 In Adult Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs PF 4937319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 08 Jun 2010 Actual patient number (50) added as reported by ClinicalTrials.gov.
- 08 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.